Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 2.1 Description of Securities Registered Under Section 12
- 4.24 Form of Convertible Loan Agreement Between the Company and Amy Sagy
- 4.25 Form of Convertible Loan Agreement Between the Company and U.S. Investors
- 4.26 Form of Price Protection Agreement Between the Company and Amy Sagy
- 4.27 Form of Price Protection Agreement Between the Company and U.S. Investors
- 4.28 Form of Registration Rights Agreement
- 4.29 Form of Warrant Issued by the Company to Amy Sagy and U.S. Investors Pursuant to the Convertible Loan Agreement
- 4.30 Form of Securities Purchase Agreement Dated As of February 13, 2020 by and Between the Company and the Purchasers Named Therein
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Consent of Kesselman & Kesselman, a Member Firm of Pricewaterhousecoopers International Limited, Independent Registered Public Accounting Firm
- Download Excel data file
- View Excel data file
CLGN similar filings
Filing view
External links
Exhibit 13.1
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350
In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2019 (the “Report”) by CollPlant Biotechnologies Ltd. (the “Company”), the undersigned, as Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) | the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: April 1, 2020
/s/ Yehiel Tal | ||
Name: | Yehiel Tal | |
Title: | Chief Executive Officer |